Literature DB >> 20039805

Cardiac risk: not so simple.

Judith A Aberg, Heather Ribaudo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20039805      PMCID： PMC2945522          DOI： 10.1086/649898

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  11 in total

1.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  A definition of causal effect for epidemiological research.

Authors:  M A Hernán
Journal:  J Epidemiol Community Health       Date:  2004-04       Impact factor: 3.710

3.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Authors:  Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

Review 4.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

5.  Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Authors:  Cindy H Brothers; Jaime E Hernandez; Amy G Cutrell; Lloyd Curtis; Mounir Ait-Khaled; Steve J Bowlin; Sara H Hughes; Jane M Yeo; Didier H Lapierre
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

6.  Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Authors:  Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

7.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

8.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

9.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Authors: 
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226
View more
  5 in total

1.  Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Authors:  Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

Authors:  C Charneira; N M Grilo; S A Pereira; A L A Godinho; E C Monteiro; M M Marques; A M M Antunes
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.

Authors:  Katleen de Gaetano Donati; Roberto Cauda; Licia Iacoviello
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-11       Impact factor: 2.576

Review 4.  Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.

Authors:  Mario Cruciani; Marina Malena
Journal:  Patient Prefer Adherence       Date:  2015-02-17       Impact factor: 2.711

5.  Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study.

Authors:  Chanelle M Diaz; Eddy R Segura; Paula M Luz; Jesse L Clark; Sayonara R Ribeiro; Raquel De Boni; Leonardo Eksterman; Rodrigo Moreira; Judith S Currier; Valdiléa G Veloso; Beatriz Grinsztejn; Jordan E Lake
Journal:  BMC Infect Dis       Date:  2016-08-08       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.